Navigation Links
New Treatment for 'Lazy Eye' Shows Promise
Date:3/4/2008

U.S., Chinese project finds 90% of vision gains retained 1 year after therapy

TUESDAY, March 4 (HealthDay News) -- A new treatment for lazy eye shows promise in adults, say American and Chinese researchers who found the therapy worked well in 20-year-old volunteers.

Lazy eye, also known as amblyopia, has been considered irreversible after age 8. Many people with the condition, especially those in developing countries, are diagnosed too late for conventional treatment with an eye patch, the researchers noted.

This new method, called perceptual learning, involves training with a simple visual task to improve vision.

A pilot trial at a Beijing hospital found that 28 of 30 patients showed dramatic gains after a 10-day course of treatment with the new method, said research group leader Zhong-Lin Lu, a University of Southern California neuroscientist.

"After training, they start to use both eyes. Some people got to 20/20. By clinical standards, they're completely normal. They're not amblyopes anymore," Lu said in a prepared statement.

The gains among the patients averaged two to three lines on a standard eye chart. Previous research found that the improvement is long-lasting, with 90 percent of vision gain retained at least one year after the therapy.

The research was described in a study published in this week's online issue of the Proceedings of the National Academy of Sciences.

Amblyopia, which can't be corrected with glasses, affects about 3 percent of people. Symptoms of the disorder include poor vision in one eye, poor depth perception, difficulty seeing three-dimensional objects, and poor motion sensitivity. Amblyopia is caused by poor transmission of images from the eye to the brain during early childhood, leading to abnormal brain development, according to background information in a new release about the research.

While this new perceptual learning thera
'/>"/>

Copyright©2008 ScoutNews,LLC.
All rights reserved  

Page: 1 2

Related medicine news :

1. New treatment effective in counteracting cocaine-induced symptoms
2. New treatment boosts muscle function in myasthenia gravis
3. Broad-based group of physicians calls for improvement in stroke treatment
4. Cranberry Could Juice Up Ovarian Cancer Treatment
5. Non-medicinal treatment touted for pre-schoolers with ADHD
6. Nonmedicinal treatment touted for preschoolers with ADHD
7. U of M study: Early treatment can reverse heart damage
8. Biologic treatment for rheumatoid arthritis and the risk of cancer
9. New Treatment Explored for Cluster Headaches
10. Thailand: Partners Open Free AIDS Treatment Clinic in Renowned AIDS Temple in Lop Buri
11. 4-Star Gen. Barry Mccaffrey, Former U.S. Drug Czar, to Keynote Recovery Happens! Rally for Treatment: Wed., Sept. 5, 11 Am, State Capitol West Steps, Sacramento
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Treatment for 'Lazy Eye' Shows Promise
New Treatment for 'Lazy Eye' Shows Promise
Breaking Medicine Technology:Helix BioPharma Reports On 2009 Annual General Meeting 2Helix BioPharma Reports On 2009 Annual General Meeting 3NOVAVAX Announces Closing of Public Offering of 6,800,000 Shares of Common Stock 2Sanofi Pasteur Global Dengue Vaccine Clinical Program Expanded in Latin America 2Sanofi Pasteur Global Dengue Vaccine Clinical Program Expanded in Latin America 3Sanofi Pasteur Global Dengue Vaccine Clinical Program Expanded in Latin America 4Sanofi Pasteur Global Dengue Vaccine Clinical Program Expanded in Latin America 5Undocumented Hispanics Face Health Care Roadblocks in U S 60405 1Undocumented Hispanics Face Health Care Roadblocks in U S 60405 2U S President 26apos 3Bs Emergency Plan for AIDS Relief Joins mHealth Alliance 60401 1U S President 26apos 3Bs Emergency Plan for AIDS Relief Joins mHealth Alliance 60401 2U S President 26apos 3Bs Emergency Plan for AIDS Relief Joins mHealth Alliance 60401 3Global Phase III Study Results Show Eribulin Meets Primary Endpoint of Overall Survival 14666 1Global Phase III Study Results Show Eribulin Meets Primary Endpoint of Overall Survival 14666 2Global Phase III Study Results Show Eribulin Meets Primary Endpoint of Overall Survival 14666 3Global Phase III Study Results Show Eribulin Meets Primary Endpoint of Overall Survival 14666 4